Relieving treatment of bronchial asthma attack in schoolchildren suffer from severe disease phenotype

Authors

DOI:

https://doi.org/10.15587/2519-4798.2017.105378

Keywords:

bronchial asthma, phenotype, children, treatment, attacks severity, methylxanthines, steroids, β2-agonists

Abstract

The study aimed at improving relieving treatment of bronchial asthma attacks in children of school age with a severe phenotype of the disease.

Materials and methods. On the base of pulmonological department of the Regional Pediatric Hospital (Chernivtsi) 57 school-age children with severe persistent asthma were examined, the attack period was determined in 48 patients (84,2 %). The severity of bronchial obstruction syndrome on patients’ admission to the hospital during the exacerbation period was assessed by point scale. Therapeutic tactics in the period of attack was assigned according to the protocol for diagnosis and treatment of asthma in children. It was determined that in patients with severe bronchial asthma for the purpose of desobstruction short-acting inhalation β2-agonists, steroids of systemic effect and methylxanthines preparations (Euphylline) were administered for oral and intravenous use in various combinations with one another. 80,0 % of children with severe bronchial asthma received steroids of systemic effect, the average duration of the course was 2,9±0,19 days. Most children with severe bronchial asthma (52,9 %) in acute period of the disease received infusion therapy with methylxanthines (Euphylline), the average duration of infusion therapy in children with severe pathology persistence lasted 3,3±0,24 days. Systemic use of glucocorticosteroids and infusion therapy with methylxanthines (Euphylline) possess distinct clinical effect, since it was considered appropriate to analyze the frequency of their administration during the first three days of hospital treatment.

Result. Relieving treatment with steroids of systemic effect during 3 days the attack severity regress was observed on the seventh day of hospitalization compared to the first day, so reduce relative risk of preserving severe bronchial obstruction reached 80 %, the reduce attributive risk was 67 % with the number of patients to be treated – 1,5 children. Intravenous Euphylline administration in children with severe variant of the disease causing regression of bronchial obstruction, the reduce relative risk of severe bronchial obstruction on the seventh day of hospitalization in patients with severe bronchial asthma reached 74 %, reduce attributive risk was 63 % with the number of patients to be treated – 1,5 children.

Conclusions. Thus, these data give reason to prove the value of initial three-day course administration of steroids of systemic effect and intravenous Euphylline administration in the treatment of attack period in children with severe bronchial asthma

Author Biographies

Mykola Garas, Bukovinian State Medical University Teatralna sq., 2, Chernivtsi, Ukraine, 58002

PhD, Associate Professor

Department of Pediatrics and Pediatric Infectious Diseases

Gennadіy Lekhkun, Bukovinian State Medical University Teatralna sq., 2, Chernivtsi, Ukraine, 58002

Lecturer

Department of Foreign Languages

Vladislav Lysenko, Bukovinian State Medical University Teatralna sq., 2, Chernivtsi, Ukraine, 58002

Student

 

Basiuk Natalia, Bukovinian State Medical University Teatralna sq., 2, Chernivtsi, Ukraine, 58002

Student

 

References

  1. Yadav, R., Yadav, H., Leong, T. (2014). Factors Influencing Acute Exacerbation of Bronchial Asthma Among Children in Malaysia. International Journal of Child Health and Nutrition, 3 (1), 11–16. doi: 10.6000/1929-4247.2014.03.01.2
  2. Pijnenburg, M. W., Baraldi, E., Brand, P. L. P., Carlsen, K.-H., Eber, E., Frischer, T. et. al. (2015). Monitoring asthma in children. European Respiratory Journal, 45 (4), 906–925. doi: 10.1183/09031936.00088814
  3. Levine, S., Wenzel, S. (2010). Narrative Review: The Role of Th2 Immune Pathway Modulation in the Treatment of Severe Asthma and Its Phenotypes. Annals of Internal Medicine, 152 (4), 232–237. doi: 10.7326/0003-4819-152-4-201002160-00008
  4. Hekking, P.-P. W., Bel, E. H. (2014). Developing and Emerging Clinical Asthma Phenotypes. The Journal of Allergy and Clinical Immunology, 2 (6), 671–680. doi: 10.1016/j.jaip.2014.09.007
  5. Joos, G. F., Barnes, P. J. (2010). Inflammatory airway diseases and clinical allergy: Inflammatory Airways Diseases and Clinical Allergy Assembly contribution to the celebration of 20 years of the ERS. European Respiratory Journal, 35 (6), 1197–1199. doi: 10.1183/09031936.00051510
  6. Fitzpatrick, A. M. (2016). Severe Asthma in Children: Lessons Learned and Future Directions. The Journal of Allergy and Clinical Immunology, 4 (1), 11–19. doi: 10.1016/j.jaip.2015.10.008
  7. Jackson, D. J., Sykes, A., Mallia, P., Johnston, S. L. (2011). Asthma exacerbations: Origin, effect, and prevention. Journal of Allergy and Clinical Immunology, 128 (6), 1165–1174. doi: 10.1016/j.jaci.2011.10.024
  8. Mallia, P., Johnston, S. L. (2006). How Viral Infections Cause Exacerbation of Airway Diseases. Chest, 130 (4), 1203–1210. doi: 10.1378/chest.130.4.1203
  9. Nievas, I. F. F., Anand, K. J. S. (2013). Severe Acute Asthma Exacerbation in Children: A Stepwise Approach for Escalating Therapy in a Pediatric Intensive Care Unit. The Journal of Pediatric Pharmacology and Therapeutics, 18 (2), 88–104. doi: 10.5863/1551-6776-18.2.88
  10. Kanchongkittiphon, W., Mendell, M. J., Gaffin, J. M., Wang, G., Phipatanakul, W. (2015). Indoor Environmental Exposures and Exacerbation of Asthma: An Update to the 2000 Review by the Institute of Medicine. Environmental Health Perspectives, 123 (1), 6–20. doi: 10.1289/ehp.1307922
  11. Camargo, C. A., Rachelefsky, G., Schatz, M. (2009). Managing Asthma Exacerbations in the Emergency Department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 Guidelines for the Management of Asthma Exacerbations. Proceedings of the American Thoracic Society, 6 (4), 357–366. doi: 10.1513/pats.p09st2
  12. Lang, A., Mowinckel, P., Sachs-Olsen, C., Riiser, A., Lunde, J., Carlsen, K.-H., Lodrup Carlsen, K. C. (2010). Asthma severity in childhood, untangling clinical phenotypes. Pediatric Allergy and Immunology, 21 (6), 945–953. doi: 10.1111/j.1399-3038.2010.01072.x
  13. Reddy, R. C. (2008). Severe asthma: approach and management. Postgraduate Medical Journal, 84 (989), 115–120. doi: 10.1136/pgmj.2007.063479
  14. Bezrukov, L. A., Nechitaylo, Yu. N., Cherevko, S. A. et. al.; Mozolevskogo, A. F. (Ed.) (1989). Diagnostics and treatment of acute pneumonia and acute respiratory viral infections, complicated by broncho-obstructive syndrome in children of early age. Chernivtsi, 23.
  15. FitzGerald, J., Bateman, E., Bousquet, J. (2014). Global strategy for asthma management and prevention. Available at: www.ginasthma.org
  16. Bacharier, L. B., Boner, A., Carlsen, K.-H., Eigenmann, P. A., Frischer, T. et. al. (2007). Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy, 63 (1), 5–34. doi: 10.1111/j.1398-9995.2007.01586.x
  17. Greenberg, R. S., Daniels, S. R., Flanders, W. D. et. al. (2004). Medical Epidemiology. Norwalk: Appleton & Lange, 196.
  18. Martinez, F. D. (2009). Managing Childhood Asthma: Challenge of Preventing Exacerbations. Pediatrics, 123 (3), 146–150. doi: 10.1542/peds.2008-2233d
  19. Kim, C.-K., Koh, Y. Y., Callaway, Z. (2009). The Validity of Induced Sputum and Bronchoalveolar Lavage in Childhood Asthma. Journal of Asthma, 46 (2), 105–112. doi: 10.1080/02770900802604111
  20. Cosio, B. G., Soriano, J. B. (2009). Theophylline again? Reasons for believing. European Respiratory Journal, 34 (1), 5–6. doi: 10.1183/09031936.00011309
  21. Cosio, B. G., Iglesias, A., Rios, A., Noguera, A., Sala, E., Ito, K. et. al. (2009). Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax, 64 (5), 424–429. doi: 10.1136/thx.2008.103432
  22. Clinical Trial of Low-Dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma (2007). American Journal of Respiratory and Critical Care Medicine, 175 (3), 235–242. doi: 10.1164/rccm.200603-416oc

Downloads

Published

2017-06-30

How to Cite

Garas, M., Lekhkun, G., Lysenko, V., & Natalia, B. (2017). Relieving treatment of bronchial asthma attack in schoolchildren suffer from severe disease phenotype. ScienceRise: Medical Science, (6 (14), 4–7. https://doi.org/10.15587/2519-4798.2017.105378

Issue

No. 6 (14) (2017)

Section

Medical Science

License

Copyright (c) 2017 Mykola Garas, Gennadіy Lekhkun, Vladislav Lysenko, Basiuk Natalia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.